Ted Drogendijk

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology · 2012 · 425 citations

Medicine, Pharmacology, Urology +14

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · European Urology · 2012 · 356 citations

Medicine, Pharmacology, Urology +14

RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER

L. Cardozo, M. LISEC, R. J. Millard et al. · The Journal of Urology · 2004 · 336 citations

Medicine, Pharmacology, Pharmacotherapy +17

A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial

Christopher R. Chapple, R. Martínez-García, Luigi Selvaggi et al. · European Urology · 2005 · 331 citations

Medicine, Pharmacology, Urology +11

A phase II dose-ranging study of mirabegron in patients with overactive bladder

Christopher R. Chapple, Vladimír Dvořák, Philip Van Kerrebroeck et al. · International Urogynecology Journal · 2013 · 134 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17